Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Revenue of Unity Biotechnology, Inc. (UBX)
Revenue in 2023 (TTM): $
According to Unity Biotechnology, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Unity Biotechnology, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-19,699,000 | $-37,283,000 | $-39,860,000 | $-39,860,000 |
| 2022 | $236 K | $-1,944,000 | $-38,731,000 | $-59,927,000 | $-57,747,000 |
| 2021 | $4.78 M | $1.9 M | $-54,668,000 | $-60,725,000 | $-60,039,000 |
| 2020 | $ | $-3,449,000 | $-89,103,000 | $-93,844,000 | $-91,869,000 |
| 2019 | $ | $-2,663,000 | $-89,651,000 | $-82,177,000 | $-74,873,000 |
| 2018 | $ | $-2,180,000 | $-74,218,000 | $-76,398,000 | $-76,398,000 |
| 2017 | $1.38 M | $-35,991,000 | $-44,304,000 | $-44,656,000 | $-44,656,000 |
| 2016 | $ | $-153,000 | $-28,068,000 | $-30,404,000 | $-30,404,000 |